1T02

Crystal structure of a Statin bound to class II HMG-CoA reductase

Summary for 1T02

• Entry DOI: 10.2210/pdb1t02/pdb
• Related: 1qax 1qay 1r31 1r7i
• Descriptor: 3-hydroxy-3-methylglutaryl-coenzyme A reductase, (3R,5R)-7-((1R,2R,6S,8R,8AS)-2,6-DIMETHYL-8-{[(2R)-2-METHYLBUTANOYL]OXY}-1,2,6,7,8,8A-HEXAHYDRONAPHTHALEN-1-YL)-3,5-DIHYDROXYHEPTANOIC ACID, SULFATE ION, ... (4 entities in total)
• Functional Keywords: statin, hmg-coa reductase, complex, oxidoreductase
• Biological source: Pseudomonas mevalonii
• Total number of polymer chains: 2
• Total formula weight: 91801.10

Authors

Tabernero, L.,Rodwell, V.W.,Stauffacher, C. (deposition date: 2004-04-07, release date: 2004-08-03, Last modification date: 2023-08-23)

Primary citation

Tabernero, L.,Rodwell, V.W.,Stauffacher, C.V.
Crystal structure of a statin bound to a class II hydroxymethylglutaryl-CoA reductase.
J.Biol.Chem., 278:19933-19938, 2003

PubMed Abstract: Hydroxymethylglutaryl-CoA (HMG-CoA) reductase is the primary target in the current clinical treatment of hypercholesterolemias with specific inhibitors of the "statin" family. Statins are excellent inhibitors of the class I (human) enzyme but relatively poor inhibitors of the class II enzymes of important bacterial pathogens. To investigate the molecular basis for this difference we determined the x-ray structure of the class II Pseudomonas mevalonii HMG-CoA reductase in complex with the statin drug lovastatin. The structure shows lovastatin bound in the active site and its interactions with residues critically involved in catalysis and substrate binding. Binding of lovastatin also displaces the flap domain of the enzyme, which contains the catalytic residue His-381. Comparison with the structures of statins bound to the human enzyme revealed a similar mode of binding but marked differences in specific interactions that account for the observed differences in affinity. We suggest that these differences might be exploited to develop selective class II inhibitors for use as antibacterial agents against pathogenic microorganisms.

PubMed: 12621048
DOI: 10.1074/jbc.M213006200

Experimental method

X-RAY DIFFRACTION (2.6 Å)